PMID

Data

Article Title

Organization

Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.

Bristol-Myers Squibb

Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor.

Universidade Federal Fluminense

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Bristol-Myers Squibb R & D

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Bristol-Myers Squibb Research & Development

Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.

Bristol-Myers Squibb R & D

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.

Bristol-Myers Squibb Research & Development

The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins.

Campus

Novel phenylalanine derived diamides as Factor XIa inhibitors.

Bristol-Myers Squibb

Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.

TBA

Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Bristol-Myers Squibb

Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.

Bristol-Myers Squibb

Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.

Universidade De Lisboa

Development of new cyclic plasmin inhibitors with excellent potency and selectivity.

Philipps University Marburg

Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development.

Universit£

Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.

Sanofi Pharmaceuticals

Protease inhibitors: current status and future prospects.

University Of Queensland

Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.

Klinikum Der Friedrich-Schiller-Universit£T Jena

Synthesis and biological activity of ketomethylene pseudopeptide analogues as thrombin inhibitors.

Thrombosis Research Institute

The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.

Novartis Horsham Research Centre

Synthesis of potent and selective inhibitors of human plasma kallikrein.

The Procter & Gamble

The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.

Universit£T Bielefeld

 

Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitors

TBA

9-hydroxyazafluorenes and their use in thrombin inhibitors.

Merck Research Laboratories

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Abbott Laboratories

Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.

Abbott Laboratories

N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.

Millennium Pharmaceuticals

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.

Millennium Pharmaceuticals

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.

Millennium Pharmaceuticals

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.

Millennium Pharmaceuticals

Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.

Millennium Pharmaceuticals

Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.

Millennium Pharmaceuticals

4-Heterocyclohexanone-based inhibitors of the serine protease plasmin.

Brown University

Highly efficient and versatile synthesis of libraries of constrained beta-strand mimetics.

Molecumetics

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.

Thrombosis Research Institute

New orally active serine protease inhibitors.

Minase Research Institute

New leupeptin analogues: synthesis and inhibition data.

University Of Arkansas

Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.

Durham University

Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.

University Of Queensland